|
<10 mm
(n = 26)
|
≥10 mm
(n = 27)
|
|
Preoperative clinical T-stage, n (%)
T1c
T2
T3
|
21 (80.8)
4 (15.4)
1 (3.8)
|
21 (77.8)
6 (22.2)
0
|
0.728 ^
|
Pathological T-stage,
n (%)
T2
T3
|
21 (80.8)a
5 (19.2) a
|
11 (40.7) b
16 (59.3) b
|
0.003 #
|
Biopsy-ISUP grade,
n (%)
|
|
|
0.919 ^
|
I |
10 (38.5) |
9 (33.3) |
|
II |
11 (42.3) |
12 (48.1) |
|
III |
4 (15.4) |
4 (11.1) |
|
IV |
1 (3.8) |
2 (7.4) |
|
RP-ISUP grade, n (%) |
|
|
0.313 ^ |
I |
3 (11.5) |
5 (18.5) |
|
II |
15 (57.7) |
10 (37.0) |
|
III |
8 (30.8) |
10 (37.0) |
|
IV |
0 |
2 (7.4) |
|
Gleason upgrade, n (%) |
10 (38.5) |
10 (37.0) |
0.915
#
|
csPCa |
|
|
|
EPE, n (%) |
5 (19.2) |
17 (63.0) |
0.001
#
|
SM, n (%) |
3 (11.5) |
13 (48.1) |
0.004
#
|
SVI, n (%) |
1 (3.8) |
3 (11.1) |
0.610 ^ |
Lymph node metastases, n(%) |
0 |
1 (3.7) |
1.000 ^ |